MADRIGAL PHARMACEUTICALS, INC. — Director's Dealing 2022

Dec 29, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK: 0001157601
Period of Report: 2022-12-23

Reporting Person: Sukhija Remy (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-23	Common Stock	M	30000	$60.26	Acquired	30000	Direct
2022-12-23	Common Stock	S	593	$266.04	Disposed	29407	Direct
2022-12-23	Common Stock	S	1107	$267.47	Disposed	28300	Direct
2022-12-23	Common Stock	S	1913	$268.50	Disposed	26387	Direct
2022-12-23	Common Stock	S	1476	$269.61	Disposed	24911	Direct
2022-12-23	Common Stock	S	2069	$270.56	Disposed	22842	Direct
2022-12-23	Common Stock	S	2084	$271.54	Disposed	20758	Direct
2022-12-23	Common Stock	S	5534	$272.68	Disposed	15224	Direct
2022-12-23	Common Stock	S	2471	$273.54	Disposed	12753	Direct
2022-12-23	Common Stock	S	3019	$274.56	Disposed	9734	Direct
2022-12-23	Common Stock	S	811	$275.70	Disposed	8923	Direct
2022-12-23	Common Stock	S	700	$276.67	Disposed	8223	Direct
2022-12-23	Common Stock	S	700	$277.83	Disposed	7523	Direct
2022-12-23	Common Stock	S	3003	$279.15	Disposed	4520	Direct
2022-12-23	Common Stock	S	2620	$279.96	Disposed	1900	Direct
2022-12-23	Common Stock	S	1000	$280.92	Disposed	900	Direct
2022-12-23	Common Stock	S	400	$282.13	Disposed	500	Direct
2022-12-23	Common Stock	S	400	$283.43	Disposed	100	Direct
2022-12-23	Common Stock	S	100	$284.65	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-23	Stock Option (Right to Buy)	$60.26	M	30000	Disposed	2030-04-01	Common Stock (30000)	Direct

Footnotes

F1: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder.

F2: All shares issued pursuant to the exercise of the options reported herein represent 30,000 shares underlying an overall option award of 60,000 shares. All exercised options had vested. As to the overall option for 60,000 shares, 25% of the shares underlying the option vested on April 1, 2021 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.76 to $266.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.98 to $267.85, inclusive.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.00 to $268.82, inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $269.01 to $269.95, inclusive.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.04 to $271.01, inclusive.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.04 to $272.01, inclusive.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.04 to $273.02, inclusive.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.04 to $274.01, inclusive.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.19 to $275.13, inclusive.

F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.24 to $276.23, inclusive.

F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.40 to $277.31, inclusive.

F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.49 to $278.13, inclusive.

F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $278.53 to $279.50, inclusive.

F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.56 to $280.42, inclusive.

F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $280.61 to $281.44, inclusive.

F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.00 to $282.20, inclusive.

F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.11 to $283.83, inclusive.